A Non-interventional multiCenter Observational Study to Evaluate tHe Effectiveness and Patient-Reported Outcomes of Ofatumumab (Kesimpta®) in patieNts With Relapsing Multiple sclerOsis Treated in Routine Care Settings in Greece (CHRONOS)
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CHRONOS
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 26 Mar 2025 Planned End Date changed from 29 Dec 2028 to 30 Dec 2028.
- 26 Mar 2025 Planned primary completion date changed from 29 Dec 2028 to 30 Dec 2028.
- 27 Dec 2024 Status changed from not yet recruiting to recruiting.